10-Q: Chemed Corporation Reports Strong Q2 Earnings Driven by VITAS Growth, Roto-Rooter Revenue Declines

Chemed Corporation's second-quarter earnings were bolstered by a significant increase in VITAS Healthcare's revenue, while Roto-Rooter experienced a decline in service revenue.

Summary

• Chemed Corporation reported a 7.6% increase in consolidated service revenues and sales for the second quarter of 2024 compared to 2023, reaching $595.88 million.
• This growth was primarily driven by a 16.7% increase in VITAS Healthcare's revenue, which was partially offset by a 5.0% decrease in Roto-Rooter's revenue.
• VITAS's revenue growth was fueled by a 14.4% increase in days-of-care and a 2.5% geographically weighted average Medicare reimbursement rate increase.
• Roto-Rooter experienced a decrease in all significant service lines, contributing to the overall revenue decline.
• Net income for the second quarter of 2024 was $70.887 million, or $4.65 per diluted share, compared to $53.377 million, or $3.51 per diluted share, in the same period of 2023.
• For the first six months of 2024, consolidated service revenues and sales increased by 6.4% to $1,185.113 million, with VITAS up 15.4% and Roto-Rooter down 5.4%.
• The company completed the acquisition of Covenant Care's hospice operations for $85 million in cash on April 17, 2024.
• Chemed has revised its full-year 2024 earnings per diluted share guidance to a range of $23.55 to $23.80, up from the previous range of $23.30 to $23.70.

Sentiment

Score: 7

Explanation: The document presents a mixed picture with strong performance in the VITAS segment but weakness in Roto-Rooter. The overall tone is positive due to the increased earnings and guidance, but the challenges in the Roto-Rooter segment and regulatory risks temper the optimism.

Positives

• VITAS Healthcare experienced strong revenue growth, driven by increased days-of-care and higher reimbursement rates.
• The acquisition of Covenant Care is expected to contribute significantly to VITAS's revenue and earnings.
• Chemed's overall net income and earnings per share showed substantial improvement compared to the same period last year.
• The company has increased its full-year earnings guidance, reflecting confidence in its performance.
• VITAS's gross margin improved significantly due to increased revenues and the expiration of the Retention Bonus Program.

Negatives

• Roto-Rooter's revenue declined across all service lines, impacting overall consolidated revenue growth.
• Roto-Rooter's net income was negatively impacted by declining revenue.
• The company is estimating $8.5 million in Medicare Cap billing limitations in calendar 2024.
• Roto-Rooter's gross margin declined slightly due to declining revenue.

Risks

• The company faces risks related to regulatory matters and litigation, particularly within the VITAS segment.
• Changes in Medicare and Medicaid reimbursement policies could impact VITAS's revenue.
• A disruption from VITAS's main pharmaceutical and medical supply vendors could adversely impact operations.
• The company is subject to various lawsuits and claims in the normal course of business.
• The company's primary market risk exposure relates to interest rate risk through its variable interest line of credit.

Future Outlook

Chemed anticipates VITAS revenue to increase by 16.0% to 17.0% in 2024, with ADC increasing by 13.0% to 14.0%. Roto-Rooter is forecasted to have a 4.0% to 5.0% revenue decline in 2024. Full-year 2024 earnings per diluted share, excluding certain non-cash and discrete items, is estimated to be in the range of $23.55 to $23.80.

Management Comments

• Management believes its liquidity and sources of capital are satisfactory for the Company's needs in the foreseeable future.
• Management anticipates that operating income and cash flows will be sufficient to operate the business and meet commitments for the foreseeable future.

Industry Context

The report highlights the ongoing challenges in the healthcare industry, particularly the shortage of licensed healthcare workers, which impacted VITAS. The hospice care sector is also subject to regulatory scrutiny, as evidenced by the ongoing audit and repayment demand. The plumbing services industry, where Roto-Rooter operates, is experiencing a downturn in demand.

Comparison to Industry Standards

• The VITAS segment's revenue growth of 16.7% in Q2 2024 is strong compared to the average growth rate of the hospice industry, which is typically in the single digits.
• The company's adjusted EBITDA margin of 20.1% in Q2 2024 is above the industry average for healthcare service providers.
• Roto-Rooter's revenue decline of 5.0% in Q2 2024 is worse than the average performance of companies in the plumbing and home services sector, which have generally seen flat or slightly positive growth.
• The company's stock repurchase program is a common practice among large public companies, but the amount of shares repurchased is relatively small compared to the company's market capitalization.

Legal Proceedings

• VITAS is one of a group of hospice providers selected by the Office of the Inspector Generals (OIG) Office of Audit Services (OAS) for inclusion in an audit of the provision of elevated level-of-care hospice services.
• VITAS received a demand letter from its Medicare Administrative Contractor (MAC) seeking repayment of $50.3 million.
• The company is subject to various lawsuits and claims in the normal course of business.

Stakeholder Impact

• Shareholders will benefit from the increased earnings and improved guidance.
• Employees at VITAS will benefit from the growth and expansion of the business.
• Customers of VITAS will continue to receive hospice care services.
• Customers of Roto-Rooter may experience changes in service availability due to the revenue decline.
• Creditors will be reassured by the company's strong financial position and compliance with debt covenants.

Next Steps

• The company will continue to monitor and manage the impact of the Medicare cap on VITAS's revenue.
• Chemed will focus on integrating the newly acquired Covenant Care operations into VITAS.
• The company will continue to evaluate cash utilization alternatives, including share repurchase, debt repurchase, acquisitions and increased dividends.
• Chemed will continue to defend itself vigorously in the ongoing audit and legal matters.

Key Dates

Keywords

Chemed, VITAS Healthcare, Roto-Rooter, hospice care, plumbing services, revenue, earnings, acquisition, Medicare, Medicaid